Kancera
  • Svenska
  • Home
  • About us
    • Statement from the CEO
    • Business model
    • Management
    • Board of directors
  • Research&Development
    • R&D portfolio
    • Fractalkine project
      • The problem
      • The solution
      • This is how KAND567 works
      • Next step
      • The future
    • Scientific publications
  • Investors
    • The share
    • Press releases
    • Reports
      • Principles and definitions
    • Calendar
    • Corporate Governance
      • Articles of association
      • General meeting
      • Board of directors committee
      • Board of directors
      • CEO and management
      • Auditors
    • Subscribe
  • Press
    • Press releases
    • Images and logos
    • Subscribe
    • News
    • Press contact
  • Contact
    • Careers
Select Page

Interim report for the first quarter 2020, 1 januari-31 March 2020 Kancera AB (publ.), org.nr. 556806-8851.

by kancerawebedit | Jun 10, 2020

First quarter in brief 1 January – 31 March 2020 Net sales for the period (January to March) amounted to SEK 0,04 million (3,1). R&D costs for the period amounted to SEK 9,7 million (10,2). Operating profit for the period amounted to SEK -11,1 million (-7,9)....

Delårsrapport för första kvartalet 2020, 1 januari – 31 mars 2020

by kancerawebedit | May 22, 2020

Första kvartalet i korthet 1 januari – 31 mars 2020 Nettoomsättning för perioden (januari till mars) uppgick till 0,04 Mkr (3,1 Mkr). FoU-kostnader för perioden uppgick till 9,7 Mkr (10,2 Mkr). Rörelseresultatet för perioden uppgick till -11,1 Mkr (-7,9 Mkr). Resultat...

INTERIM REPORT FOR THE FIRST QUARTER 2019, 1 January – 31 March 2019

by kancerawebedit | May 24, 2019

First quarter in brief 1 January – 31 March 2019 Net sales for the period (January to March) amounted to SEK 0.0 million (SEK 0.0 million) R&D costs for the period amounted to SEK 10,2 million (SEK 11,8 million). Operating profit for the period amounted to SEK...

Delårsrapport för första kvartalet 2019. 1 januari – 31 mars 2019

by kancerawebedit | May 24, 2019

FÖRSTA KVARTALET 1 JANUARI – 31 MARS I KORTHET Nettoomsättning för perioden (januari till mars) uppgick till 0,0 MSEK (0,0 MSEK) FoU-kostnader för perioden uppgick till 10,2 Mkr (11,8 Mkr). Rörelseresultatet för perioden uppgick till -7,9 Mkr (-12,7 Mkr). Resultat...

INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 31st March 2018

by kancerawebedit | Jun 7, 2018

PERIOD 1 JAN – 31 MARCH 2018 IN BRIEF • Net sales amounted to SEK 0 million (0 million) • R & D expenses amounted to SEK 11.8 million (8.3 M) • Operating profit amounted to SEK -12.5 million (-9.7 million) • Profit after financial items amounted to SEK -12.5...
« Older Entries

Swedish

Recent Comments

    Archives

    Categories

    • No categories

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

     

    Download our reports here

    Read all press releases

    Check out the latest news

    Click on the image to download our latest report

    Kancera AB

    Karolinska Institutet Science Park
    Nanna Svartz Väg 4
    SE-171 65 Solna, Sweden
    Tel: +46 (0)850 12 60 80

    This site uses cookies. Follow the link below for more information and our web policy:
    • Website policy
    • Svenska
    Copyright 2017 Kancera AB